• Title/Summary/Keyword: Planning target volume

Search Result 284, Processing Time 0.026 seconds

Feasibility and response of helical tomotherapy in patients with metastatic colorectal cancer

  • Bae, Sun Hyun;Moon, Seong Kwon;Kim, Yong Ho;Cho, Kwang Hwan;Shin, Eung Jin;Lee, Moon Sung;Ryu, Chang Beom;Ko, Bong Min;Yun, Jina
    • Radiation Oncology Journal
    • /
    • v.33 no.4
    • /
    • pp.320-327
    • /
    • 2015
  • Purpose: To investigate the treatment outcome and the toxicity of helical tomotherapy (HT) in patients with metastatic colorectal cancer (mCRC). Materials and Methods: We retrospectively reviewed 18 patients with 31 lesions from mCRC treated with HT between 2009 and 2013. The liver (9 lesions) and lymph nodes (9 lesions) were the most frequent sites. The planning target volume (PTV) ranged from 12 to 1,110 mL (median, 114 mL). The total doses ranged from 30 to 70 Gy in 10-30 fractions. When the ${\alpha}/{\beta}$ value for the tumor was assumed to be 10 Gy for the biologically equivalent dose (BED), the total doses ranged from 39 to $119Gy_{10}$ (median, $55Gy_{10}$). Nineteen lesions were treated with concurrent chemotherapy (CCRT). Results: With a median follow-up time of 16 months, the median overall survival for 18 patients was 33 months. Eight lesions (26%) achieved complete response. The 1- and 3-year local progression free survival (LPFS) rates for 31 lesions were 45% and 34%, respectively. On univariate analysis, significant parameters influencing LPFS rates were chemotherapy response before HT, aim of HT, CCRT, PTV, BED, and adjuvant chemotherapy. On multivariate analysis, $PTV{\leq}113mL$ and $BED>48Gy_{10}$ were associated with a statistically significant improvement in LFPS. During HT, four patients experienced grade 3 hematologic toxicities, each of whom had also received CCRT. Conclusion: The current study demonstrates the efficacy and tolerability of HT for mCRC. To define optimal RT dose according to tumor size of mCRC, further study should be needed.

Fabrication of a Patient-Customized Helmet with a Three-Dimensional Printer for Radiation Therapy of Scalp

  • Oh, Se An;Lee, Chang Min;Lee, Min Woo;Lee, Yeong Seok;Lee, Gyu Hwan;Kim, Seong Hoon;Kim, Sung Kyu;Park, Jae Won;Yea, Ji Woon
    • Progress in Medical Physics
    • /
    • v.28 no.3
    • /
    • pp.100-105
    • /
    • 2017
  • The purpose of the present study was to develop and evaluate patient-customized helmets with a three-dimensional (3D) printer for radiation therapy of malignant scalp tumors. Computed tomography was performed in a case an Alderson RANDO phantom without bolus (Non_Bolus), in a case with a dental wax bolus on the scalp (Wax_Bolus), and in a case with a patient-customized helmet fabricated using a 3D printer (3D Printing_Bolus); treatment plans for each of the 3 cases were compared. When wax bolus was used to fabricate a bolus, a drier was used to apply heat to the bolus to make the helmet. $3-matic^{(R)}$ (Materialise) was used for modeling and polyamide 12 (PA-12) was used as a material, 3D Printing bolus was fabricated using a HP JET Fusion 3D 4200. The average Hounsfield Unit (HU) for the Wax_Bolus was -100, and that of the 3D Printing_Bolus was -10. The average radiation doses to the normal brain with the Non_Bolus, Wax_Bolus, and 3D Printing_Bolus methods were 36.3%, 40.2%, and 36.9%, and the minimum radiation dose were 0.9%, 1.6%, 1.4%, respectively. The organs at risk dose were not significantly difference. However, the 95% radiation doses into the planning target volume (PTV) were 61.85%, 94.53%, and 97.82%, and the minimum doses were 0%, 77.1%, and 82.8%, respectively. The technique used to fabricate patient-customized helmets with a 3D printer for radiation therapy of malignant scalp tumors is highly useful, and is expected to accurately deliver doses by reducing the air gap between the patient and bolus.

The Comparison of Dose Distribution on Radiation Therapy between IMRT and VMAT in Modified Radical Mastectomy Patients (전유방절제술 환자에서 IMRT와 VMAT을 이용한 방사선치료시 선량 분포의 비교)

  • Ko, Hye-Jin;Kim, Young-Jae;Jang, Seong-Joo
    • The Journal of the Korea Contents Association
    • /
    • v.14 no.8
    • /
    • pp.225-232
    • /
    • 2014
  • Underwent on modified radical mastectomy(MRM) and radiation therapy, it affects increasing rates of chronic morbidity, because of including chest wall and internal mammary nodes(IMNs). It causes the high absorbed dose on heart and ipsilateral lung. Thus in this study, we compared dose distributions through utilizing the intensity modulated radiation therapy(IMRT) and the volumetric modulated arc therapy(VMAT). We selected 10 breast cancer patients at random who took MRM and radiation therapy. Treatment plannings were done by using IMRT and VMAT from each patient ranging supraclavicular lymphnodes(SCL) and IMNs. After that we analysed the planning target volume(PTV)'s conformity and absorbed doses on heart and lungs. As a results, PTV conformities were indicated the same patten(p<0.05) in both plans. In case of Lt breast cancer patients, the dose maximum regions of the heart were more lesser in VMAT technique rather than the IMRT(p<0.05). Also, the maximum dose areas of lungs were lesser in VMAT technique rather than the IMRT(p<0.05). Therefore, it would be safe to say that it is more effective way to adapt the VMAT technique than IMRT in such cases like involve IMNs in breast cancer patients.

A Study on the Development of Dynamic Models under Inter Port Competition (항만의 경쟁상황을 고려한 동적모형 개발에 관한 연구)

  • 여기태;이철영
    • Journal of the Korean Institute of Navigation
    • /
    • v.23 no.1
    • /
    • pp.75-84
    • /
    • 1999
  • Although many studies on modelling of port competitive situation have been conducted, both theoretical frame and methodology are still very weak. In this study, therefore, a new algorithm called ESD (Extensional System Dynamics) for the evaluation of port competition was presented, and applied to simulate port systems in northeast asia. The detailed objectives of this paper are to develop Unit fort Model by using SD(System Dynamics) method; to develop Competitive Port Model by ESD method; to perform sensitivity analysis by altering parameters, and to propose port development strategies. For these the algorithm for the evaluation of part's competition was developed in two steps. Firstly, SD method was adopted to develop the Unit Port models, and secondly HFP(Hierarchical Fuzzy Process) method was introduced to expand previous SD method. The proposed models were then developed and applied to the five ports - Pusan, Kobe, Yokohama, Kaoshiung, Keelung - with real data on each ports, and several findings were derived. Firstly, the extraction of factors for Unit Port was accomplished by consultation of experts such as research worker, professor, research fellows related to harbor, and expert group, and finally, five factor groups - location, facility, service, cargo volumes, and port charge - were obtained. Secondly, system's structure consisting of feedback loop was found easily by location of representative and detailed factors on keyword network of STGB map. Using these keyword network, feedback loop was found. Thirdly, for the target year of 2003, the simulation for Pusan port revealed that liner's number would be increased from 829 ships to 1,450 ships and container cargo volumes increased from 4.56 million TEU to 7.74 million TEU. It also revealed that because of increased liners and container cargo volumes, length of berth should be expanded from 2,162m to 4,729m. This berth expansion was resulted in the decrease of congested ship's number from 97 to 11. It was also found that port's charge had a fluctuation. Results of simulation for Kobe, Yokohama, Kaoshiung, Keelung in northeast asia were also acquired. Finally, the inter port competition models developed by ESB method were used to simulate container cargo volumes for Pusan port. The results revealed that under competitive situation container cargo volume was smaller than non-competitive situation, which means Pusan port is lack of competitive power to other ports. Developed models in this study were then applied to estimate change of container cargo volumes in competitive relation by altering several parameters. And, the results were found to be very helpful for port mangers who are in charge of planning of port development.

  • PDF

Clinical Application of the Dual Energy Photon Beam Using 6 MV and 10 MV X-ray (6MV 및 10 MV X-ray의 이중에너지를 생성하는 방사선 발생장치의 임상적 이용)

  • Lee, Myung-Za;Han, Hye-Gyeong
    • Radiation Oncology Journal
    • /
    • v.6 no.1
    • /
    • pp.93-99
    • /
    • 1988
  • Some modern accerelators provide a dual energy for photon beam treatment. The main advantages of dual energy in the treatment of rectosigmoid or rectal cancer are as fellows. 1. Dose in the critical organ such as small intestine, bladder and genital organ are reduced. 2. Presacral and perineal area is fully covered. Dose distribution analysis such as calculation of dose in a target volume, isocenter, $D_{nax}$ and dose spectrum in any region of interest are possible. Examples of plan are given and results are discussed.

  • PDF

Dosimetric Validation of the Acuros XB Advanced Dose Calculation Algorithm for Volumetric Modulated Arc Therapy Plans

  • Park, So-Yeon;Park, Jong Min;Choi, Chang Heon;Chun, Minsoo;Kim, Jung-in
    • Progress in Medical Physics
    • /
    • v.27 no.4
    • /
    • pp.180-188
    • /
    • 2016
  • Acuros XB advanced dose calculation algorithm (AXB, Varian Medical Systems, Palo Alto, CA) has been released recently and provided the advantages of speed and accuracy for dose calculation. For clinical use, it is important to investigate the dosimetric performance of AXB compared to the calculation algorithm of the previous version, Anisotropic Analytical Algorithm (AAA, Varian Medical Systems, Palo Alto, CA). Ten volumetric modulated arc therapy (VMAT) plans for each of the following cases were included: head and neck (H&N), prostate, spine, and lung. The spine and lung cases were treated with stereotactic body radiation therapy (SBRT) technique. For all cases, the dose distributions were calculated using AAA and two dose reporting modes in AXB (dose-to-water, $AXB_w$, and dose-to-medium, $AXB_m$) with same plan parameters. For dosimetric evaluation, the dose-volumetric parameters were calculated for each planning target volume (PTV) and interested normal organs. The differences between AAA and AXB were statistically calculated with paired t-test. As a general trend, $AXB_w$ and $AXB_m$ showed dose underestimation as compared with AAA, which did not exceed within -3.5% and -4.5%, respectively. The maximum dose of PTV calculated by $AXB_w$ and $AXB_m$ was tended to be overestimated with the relative dose difference ranged from 1.6% to 4.6% for all cases. The absolute mean values of the relative dose differences were $1.1{\pm}1.2%$ and $2.0{\pm}1.2%$ when comparing between AAA and $AXB_w$, and AAA and $AXB_m$, respectively. For almost dose-volumetric parameters of PTV, the relative dose differences are statistically significant while there are no statistical significance for normal tissues. Both $AXB_w$ and $AXB_m$ was tended to underestimate dose for PTV and normal tissues compared to AAA. For analyzing two dose reporting modes in AXB, the dose distribution calculated by $AXB_w$ was similar to those of AAA when comparing the dose distributions between AAA and $AXB_m$.

Comparison of Two Different Immobilization Devices for Pelvic Region Radiotherapy in Tomotherapy

  • Kim, Dae Gun;Jung, James J;Cho, Kwang Hwan;Ryu, Mi Ryeong;Moon, Seong Kwon;Bae, Sun Hyun;Ahn, Jae Ouk;Jung, Jae Hong
    • Progress in Medical Physics
    • /
    • v.27 no.4
    • /
    • pp.250-257
    • /
    • 2016
  • The purpose of this study was to compare the patient setup errors of two different immobilization devices (Feet Fix: FF and Leg Fix: LF) for pelvic region radiotherapy in Tomotherapy. Thirty six-patients previously treated with IMRT technique were selected, and divided into two groups based on applied immobilization devices (FF versus LF). We performed a retrospective clinical analysis including the mean, systematic, random variation, 3D-error, and calculated the planning target volume (PTV) margin. In addition, a rotational error (angles, $^{\circ}$) for each patient was analyzed using the automatic image registration. The 3D-errors for the FF and the LF groups were 3.70 mm and 4.26 mm, respectively; the LF group value was 15.1% higher than in the FF group. The treatment margin in the ML, SI, and AP directions were 5.23 mm (6.08 mm), 4.64 mm (6.29 mm), 5.83 mm (8.69 mm) in the FF group (and the LF group), respectively, that the FF group was lower than in the LF group. The percentage in treatment fractions for the FF group (ant the LF group) in greater than 5 mm at ML, SI, and AP direction was 1.7% (3.6%), 3.3% (10.7%), and 5.0% (16.1%), respectively. Two different immobilization devices were affected the patient setup errors due to different fixed location in low extremity. The radiotherapy for the pelvic region by Tomotherapy should be considering variation for the rotational angles including Yaw and Pitch direction that incorrect setup error during the treatment. In addition the choice of an appropriate immobilization device is important because an unalterable rotation angle affects the setup error.

Prognostic value of neutrophil-to-lymphocyte ratio in locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy

  • Park, Eun Young;Kim, Yeon-Sil;Choi, Kyu Hye;Song, Jin Ho;Lee, Hyo Chun;Hong, Sook-Hee;Kang, Jin-Hyoung
    • Radiation Oncology Journal
    • /
    • v.37 no.3
    • /
    • pp.166-175
    • /
    • 2019
  • Purpose: This study aimed to investigate neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) as prognostic factors in patients with locally advanced non-small cell lung cancer (NSCLC) who received concurrent chemoradiotherapy (CCRT). Materials and Methods: We retrospectively analyzed 66 patients with locally advanced NSCLC treated with definitive CCRT. Among these patients, 95% received paclitaxel/carboplatin or docetaxel/cisplatin. The median radiation dose was 66 Gy in 33 fractions. The NLR and PLR before/after CCRT were evaluated. The maximally selected log-rank test was used to obtain the cutoff values related to the overall survival (OS). Results: Patients with high post-CCRT NLR (>3.12) showed worse OS, locoregional progression-free survival (LRPFS), and distant metastasis-free survival (DMFS) than those with low NLR (2-year OS: 25.8% vs. 68.2%, p < 0.001; 2-year LRPFS: 12.9% vs. 33.8%, p = 0.010; 2-year DMFS: 22.6% vs. 38.2%, p = 0.030). Patients with high post-CCRT PLR (>141) showed worse OS and LRPFS than those with low PLR (2-year OS: 37.5% vs. 71.1%, p = 0.004; 2-year LRPFS: 16.5% vs. 40.3%, p = 0.040). Patients with high NLR change (>1.61) showed worse OS and LRPFS than those with low NLR change (2-year OS: 26.0% vs. 59.0%, p < 0.001; 2-year LRPFS: 6.8% vs. 31.8%, p = 0.004). The planning target volume (hazard ration [HR] = 2.05, p = 0.028) and NLR change (HR = 3.17, p = 0.025) were the significant factors for OS in the multivariate analysis. Conclusion: NLR change after CCRT was associated with poor prognosis of survival in patients with locally advanced NSCLC. An elevated NLR after CCRT might be an indicator of an increased treatment failure risk.

Patterns of recurrence after radiation therapy for high-risk neuroblastoma

  • Jo, Ji Hwan;Ahn, Seung Do;Koh, Minji;Kim, Jong Hoon;Lee, Sang-wook;Song, Si Yeol;Yoon, Sang Min;Kim, Young Seok;Kim, Su Ssan;Park, Jin-hong;Jung, Jinhong;Choi, Eun Kyung
    • Radiation Oncology Journal
    • /
    • v.37 no.3
    • /
    • pp.224-231
    • /
    • 2019
  • Purpose: To investigate the patterns of recurrence in patients with neuroblastoma treated with radiation therapy to the primary tumor site. Materials and Methods: We retrospectively analyzed patients with high-risk neuroblastoma managed with definitive treatment with radiation therapy to the primary tumor site between January 2003 and June 2017. These patients underwent three-dimensional conformal radiation therapy or intensity-modulated radiation therapy. A total of 14-36 Gy was delivered to the planning target volume, which included the primary tumor bed and the selected metastatic site. The disease stage was determined according to the International Neuroblastoma Staging System (INSS). We evaluated the recurrence pattern (i.e., local or systemic), progression-free survival, and overall survival. Results: A total of 40 patients with high-risk neuroblastoma were included in this study. The median patient age was 4 years (range, 1 to 11 years). Thirty patients (75%) had INSS stage 4 neuroblastoma. At the median follow-up of 58 months, there were 6 cases of local recurrence and 10 cases of systemic recurrence. Among the 6 local failure cases, 4 relapsed adjacent to the radiation field. The other 2 relapsed in the radiation field (i.e., para-aortic and retroperitoneal areas). The main sites of distant metastasis were the bone, lymph nodes, and bone marrow. The 5-year progression-free survival was 70.9% and the 5-year overall survival was 74.3%. Conclusion: Radiation therapy directed at the primary tumor site provides good local control. It seems to be adequate for disease control in patients with high-risk neuroblastoma after chemotherapy and surgical resection.

Is higher dose always the right answer in stereotactic body radiation therapy for small hepatocellular carcinoma?

  • Lee, Kyung Hwa;Yu, Jeong Il;Park, Hee Chul;Park, Su Yeon;Shin, Jung Suk;Shin, Eun Hyuk;Cho, Sungkoo;Jung, Sang Hoon;Han, Young Yih;Lim, Do Hoon
    • Radiation Oncology Journal
    • /
    • v.36 no.2
    • /
    • pp.129-138
    • /
    • 2018
  • Purpose: This study was conducted to compare clinical outcomes and treatment-related toxicities after stereotactic body radiation therapy (SBRT) with two different dose regimens for small hepatocellular carcinomas (HCC) ${\leq}3cm$ in size. Materials and Methods: We retrospectively reviewed 44 patients with liver-confined HCC treated between 2009 and 2014 with SBRT. Total doses of 45 Gy (n = 10) or 60 Gy (n = 34) in 3 fractions were prescribed to the 95% isodose line covering 95% of the planning target volume. Rates of local control (LC), intrahepatic failure-free survival (IHFFS), distant metastasis-free survival (DMFS), and overall survival (OS) were calculated using the Kaplan-Meier method. Results: Median follow-up was 29 months (range, 8 to 64 months). Rates at 1 and 3 years were 97.7% and 95.0% for LC, 97.7% and 80.7% for OS, 76% and 40.5% for IHFFS, and 87.3% and 79.5% for DMFS. Five patients (11.4%) experienced degradation of albumin-bilirubin grade, 2 (4.5%) degradation of Child-Pugh score, and 4 (9.1%) grade 3 or greater laboratory abnormalities within 3 months after SBRT. No significant difference was seen in any oncological outcomes or treatment-related toxicities between the two dose regimens. Conclusions: SBRT was highly effective for local control without severe toxicities in patients with HCC smaller than 3 cm. The regimen of a total dose of 45 Gy in 3 fractions was comparable to 60 Gy in efficacy and safety of SBRT for small HCC.